Xigris Best-Case Label Would Be 400,000 Patients; User Fee Date Is Oct. 27
Executive Summary
Lilly is hoping to receive Xigris labeling permitting use in approximately 400,000 severe sepsis patients per year.
You may also be interested in...
Lilly Xigris Phase IV Studies Will Enroll 14,000 Sepsis Patients
Lilly is committed to studying nearly 14,000 sepsis patients to meet its postmarketing obligations for its sepsis agent Xigris (drotrecogin alfa)
APACHE II Sepsis Score Best Indicator Of Xigris Benefit, Labeling States
The APACHE II sepsis score is the most appropriate tool to estimate the likelihood of a Xigris benefit in a particular patient, labeling for Lilly's biologic states
Lilly Xigris Phase IV Studies Will Enroll 14,000 Sepsis Patients
Lilly is committed to studying nearly 14,000 sepsis patients to meet its postmarketing obligations for its sepsis agent Xigris (drotrecogin alfa)